Patients Question How FDA Approves Medical Devices

There’s no doubt that surgically implanted medical devices can improve lives.

Hip and knee replacements can help people regain their mobility. Drug pumps can deliver doses of pain-relieving medicine on demand. And metal rods can stabilize spines and broken bones.

PhRMA Fights Six-Month Delay of New Drugs for Medicaid Members

Rep. John Lively has proposed a cost-saving and drug-management measure that would allow the Oregon Health Authority to deny new drugs that have been approved by the FDA in the past six months, while PhRMA is fighting to strip the provision from legislation that passed the House unanimously. The measure does not impact CCOs, which can determine the suitability of most drugs.

The Pharmaceutical Research and Manufacturers of America is asking for a midstream change to legislation that allows the Oregon Health Authority to deny payment for high-priced blockbuster drugs for six months after they’ve been approved by the U.S. Food and Drug Administration.

Buehler Shepherds Right-To-Try Bill to House Floor with Limitations

The libertarian measure would give patients access to unapproved drugs if they have been given less than a year to live. Patients would be on their own with the drugs and have to assume responsibility for any complications, which insurers would not have to cover.

The House Health Committee greenlighted the libertarian “right-to-try” initiative, sending an amended House Bill 2300 to the floor on a unanimous vote.

Oregon House Health Committee Grapples with Out-of-Control Drug Costs

This article is for premium subscribers. Please sign up here for a tax-deductible subscription. 

If you're a premium subscriber, sign in below. 

The committee is considering three bills aimed at tackling one of the biggest cost drivers in medicine today -- outrageously priced biological wonder drugs. One bill would prevent health insurers from gouging consumers who need these medications. A second bill would require pharmaceuticals to report their profit information to the Oregon Health Authority. The third bill would free pharmacists to dispense FDA-approved biosimilars without special state barriers.

The out-of-control and arbitrary pricing of designer prescription drugs dominated the House Health Committee on Monday, with three bills aimed at helping consumers, the state and health insurers to address the problem.


Subscribe to fda